Momenta Delays on Adalimumab In A Bid To Save On Costs
US filing previously slated for the current quarter is pushed back to an undisclosed date, with costs in mind; Momenta also plans to raise up to US$177.5 million through public offering.
US filing previously slated for the current quarter is pushed back to an undisclosed date, with costs in mind; Momenta also plans to raise up to US$177.5 million through public offering.